Recent Headlines
Within Biopharmaceuticals & Biotherapeutics

Newsletter XVII is Available from MoBiTec GmbH, Germany

MoBiTec's periodical Newsletter, issued several times a year, informs about new, exciting products in the categoríes vector systems and gene expression, genomics, proteomics, fluorescence applications, cell biology, labware, and more. - September 19, 2014 - MoBiTec GmbH

Creative Biomart Morning Talk for Mutagenesis Services

Creative BioMart, a world leading Biotech Company, has conducted a morning talk to discuss its mutagenesis. This talk lasted for nearly one hour. Mutagenesis is a fundamentally important DNA manipulation technique. It involves changing the base sequence of the DNA molecule, usually for the... - September 18, 2014 - Creative Biomart

VIRUN® NutraBIOsciences™ Granted Patent 261124 in India, Redesigns Website, Omega-3 Summit at Supply Side West and CEO is Again Scheduled to Speak at Cal Poly Pomona

VIRUN has been granted patent number 261124 titled, Compositions Comprising a Mucoadhesive Protein and an Active Principle for Mucosal Delivery of Said Agents. Also, VIRUN has re-designed their website to include brands, a product description page, video as well as a news and PR page. Included in the newly renovated website is an events page; with the growing interest in VIRUN, such as scheduled forums, lectures, expos and webinars, it was imperative this new website share these experiences. - September 11, 2014 - VIRUN

F2G Limited, the UK-Based Antifungal Drug Discovery and Development Company, Announces a Major Funding Award from the Technology Strategy Board’s Biomedical Catalyst

F2G Limited, the UK-based antifungal drug discovery and development company, today announced a major funding award from the Technology Strategy Board’s Biomedical Catalyst. - September 11, 2014 - F2G Ltd

Creative Biomart Newly Introduced Its Stable Cell Line Service

Creative Biomart today has given an announcement that they would release their new service-stable cell line service in this very day to meet their customer’s need. Stable cell lines are essential for protein and antibody and cell-based assays. But the processes required for the generation of... - September 11, 2014 - Creative Biomart

Xeno Diagnostics Adds Dr. Daniel Wierda as Director of Research and Development

Addition of Top Talent Strengthens Fast-Growing Indianapolis Biotech CRO - September 10, 2014 - Xeno Diagnostics, LLC

F2G Ltd, the UK Antifungal Drug Discovery & Development Company, Today Announces Commencement of a Phase 1 Single Ascending Dose Study of a Novel Antifungal Agent

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/oral systemic antifungal (F901318) with the commencement of a Phase I clinical study. This study initiates the IV Phase I clinical development of F901318 with the oral... - September 04, 2014 - F2G Ltd

MoBiTec to Attend the 4. Joint Conference of the VAAM and DGHM in Dresden, Germany, Oct. 5-8, 2014

This year the DGHM (Society of Hygiene and Microbiology) and the VAAM (Association for General and Applied Microbiology), the biggest German societies in the area of microbiology, hold their annual conference as a joint conference in Dresden. - September 04, 2014 - MoBiTec GmbH

Creative Biomart Newly Released a Bunch of Over-Expression Lysates

Official marketing staff of Creative Biomart has announced today of their new products release for over-expression lysates. According to its official announcement, this new release is mainly an enhancement of their lysates product. Nearly 9,000 of products have been added in this launch such as... - September 02, 2014 - Creative Biomart

MoBiTec, Germany, Offers Clickable Isoprenoids Manufactured by Echelon Biosciences, USA, Representing Exclusive Valuable Tools for Isoprenoid and Cancer Research

Isoprenoids are organic compounds composed of two or more units of hydrocarbons, with each unit consisting of five carbon atoms arranged in a specific pattern. Isoprenoids play widely varying roles in physiological processes of plants and animals. - August 31, 2014 - MoBiTec GmbH

Mac’s SET the PACE Race Superhero for a Day 5K Run/Walk

Join the Mac’s SET the PACE Race at Washington Park in Denver, CO. This event honors patients, survivors and their family members. Increasing awareness of prostate cancer and the importance of early detection with a fun day of activities for the whole family. - August 29, 2014 - Prostate Conditions Education Council

MoBiTec, Germany, Announces Availability of Ebola Virus (EBOV) Real Time RT-PCR Kit

Ebola hemorrhagic fever (Ebola HF) is a severe, often fatal disease in humans and nonhuman primates, caused by infection with Ebolavirus. The recent Ebola outbreak in West Africa is one of the largest Ebola outbreaks in history. - August 28, 2014 - MoBiTec GmbH

NC COIN Promotes Karen Shank to Business Development Director

Pharma, Software, and Medical Technology Veteran Developing K-12 Programming, Expanding Membership Base of Nonprofit Idea Accelerator - August 27, 2014 - COIN

Creative Biomart Introduced Immobilized Enzyme Service

On August 24, 2014, Creative Biomart has introduced their novel service of immobilized enzymes. This novel service is based on a revolutionary new platform, combining affinity tag binding with inert porous materials, designed especially for biocatalysis application in any organic solvent or... - August 27, 2014 - Creative Biomart

Braasch Biotech to Participate at Informa's 9th Annual Veterinary Vaccine Conference

Braasch's Biotech's Dr. Keith Haffer to host seminar on adjuvants at Informa's Veterinary Vaccine Conference in December. - August 25, 2014 - Braasch Biotech LLC

MoBiTec GmbH to Attend Horizons in Molecular Biology Meeting in Goettingen, Germany, Sep 15-18, 2014

Horizons in Molecular Biology is an international symposium in the field of molecular life sciences, organized by PhD students of the MSc/PhD Molecular Biology Program - International Max Planck Research School (IMPRS). - August 24, 2014 - MoBiTec GmbH

Synpromics Announces Highly Successful Results from Plant Science Projects

Synpromics Limited, a privately held, Scottish-based synthetic biology company today announced that it has successfully generated several highly effective synthetic promoters for use in plants. - August 22, 2014 - Synpromics Ltd

Cheers—Creative Biomart Launches High-Throughput Protein Production

The marketing chief staff of Creative Biomart has announced today that they will release the high-throughput protein production service on this very day in the aim of helping speed up their customer’s protein production project. Protein expression is widely used in the production of... - August 22, 2014 - Creative Biomart

Creative Biomart Launches Novel Service for Protein Labeling

On August 18, Creative Biomart had launched a novel service that is site-specific and custom labeling for protein labeling. This new service includes C-terminal labeling, N-terminal labeling, and Labeling at glycosylation sites. The launch of the site-specific and custom labeling service was said... - August 22, 2014 - Creative Biomart

Creative Biomart Signed Industrial Enzymes Agreement

Creative Biomart signed an Industrial Enzymes Agreement with a UK Industrial giant (the name of the company is not allowed to be exposed according to the agreement). On the basis of this agreement, Creative Biomart is going to provide High-temperature Alpha-amylase for beer, Mid-temperature... - August 20, 2014 - Creative Biomart

MMS Holdings and Oncology Trials Insights Form Strategic Partnership to Deliver Comprehensive Oncology Support Services

MMS Holdings Inc., a global clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries, and Oncology Trials Insights (OTI), an organization of oncology key opinion leaders that architect superior clinical trial... - August 18, 2014 - MMS Holdings Inc.

Polmacoxib Demonstrates Prevention and Treatment Effects in Colorectal Cancer

CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has reported a positive outcome from an investigational preclinical research conducted, in part, at the University of Texas MD Anderson Cancer Center by Dr. Raymond N. DuBois’ laboratory where the... - August 15, 2014 - CrystalGenomics, Inc.

Creative Diagnostics Expands Its Antibody Pairs Offering

By the time of the release, Creative Diagnostics has expanded its antibody pairs to over 40,000. - August 14, 2014 - Creative Diagnostics

Creative Diagnostics Expands Database of Antibody Pairs

The expanding of Creative Diagnostics' database of antibody pairs could largely save the preparation time of investigators. - August 01, 2014 - Creative Diagnostics

CHI Announces Its 2nd Annual FAST: Functional Analysis & Screening Technologies Congress, November 17-19, 2014, Boston, MA

Keynote Presentations Delivered by George Church, Anna Collén, Meir Click and More - July 29, 2014 - Cambridge Healthtech Institute

MoBiTec, Germany, Announces Availability of Human Herpesvirus-6 (HHV-6) Assay Kits

Human herpesvirus (HHV-) 6 has been associated with various neurological diseases, including encephalitis, meningitis, epilepsy, and multiple sclerosis. MoBiTec partners with VIDIA, Czech Republic, to offer HHV-6 assay kits worldwide. - July 25, 2014 - MoBiTec GmbH

Creative Diagnostics Announces New Big Promotion Activity for Antibodies

Creative Diagnostics's July Big Promotion is open to customers around the world. - July 22, 2014 - Creative Diagnostics

MoBiTec GmbH Teams Up with Protobios to Offer Epitope Mapping Service Using Mimotope Variation Analysis (MVA) Technology

MoBiTec, Germany, partners with the Estonian biotechnology company Protobios to offer Mimotope Variation Analysis (MVA)-based antibody epitope mapping service to scientists worldwide. - July 19, 2014 - MoBiTec GmbH

Case Study: Stem Cells vs Coronary Artery Bypass Surgery in a Patient with Multi-Vessel Disease 6 Year Follow Up

Stem cells outperform heart bypass surgery. A heart patient treated with his own stem cells instead of undergoing coronary bypass surgery is exceeding all expectations 6 years after his adult stem cell treatment. - July 17, 2014 - Regenocyte Worldwide

Hormel Foods Specialty Products Division and VIRUN®, Granted Patent No. 8,741,373

VIRUN® and the Specialty Products Division at Hormel Foods were granted Patent number 8,741,373, Composition for Non-Polar Compounds. This particular patent allows unwavering high oil load encapsulation of non-polar compounds, such as Omega-3 EPA and DHA, CoQ10, Vitamins A, D, E, K, Carotenoids such as Lutein, Beta Carotene or Astaxanthin into certain water soluble and stable foods and beverages. - July 09, 2014 - VIRUN

Recursion Pharmaceuticals Announces Funding for Rett Syndrome Research

Recursion Pharmaceuticals has received support for focused work to identify a treatment for Rett Syndrome by the Rett Syndrome Research Trust. Recursion will apply its innovative drug discovery platform immediately to investigate the gene MECP2 in an effort to identify new therapeutics for the condition. - July 09, 2014 - Recursion Pharmaceuticals

Mirus Reagent Agent® Now on MoBiTec Website - Find the Appropriate Transfection Reagent for Your Cell Line and Experiment

MoBiTec GmbH, Germany, together with the transfection experts of Mirus Bio, USA, brings you the Reagent Agent® - a tool designed to determine the best solution for delivery of any nucleic acids into any cell type, including hard-to-transfect cell lines and primary cells. - July 05, 2014 - MoBiTec GmbH

CrystalGenomics Receives KRW 13 Billion in Strategic Investment from the Global Pharmaceutical Industry Development Fund

CrystalGenomics, Inc., a late clinical stage biopharmaceutical company focused on developing and commercializing novel drugs for therapeutic areas of unmet medical needs, has just announced that it has received KRW 13 billion (USD 12.8 Million) from the Global Pharmaceutical Industry Development... - June 27, 2014 - CrystalGenomics, Inc.

AveXis Announces Dosing of First Patient for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children’s Hospital

AveXis, Inc., a synthetic biology platform company, today announced that the first patient in the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now been enrolled and dosed by Nationwide Children’s Hospital. This trial utilizes chariSMA, the gene therapy product developed... - June 26, 2014 - AveXis Inc.

iPathwayGuide Now Available in Illumina’s BaseSpace Apps

Advaita Bioinformatics today announced the addition of its iPathwayGuide application to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis. iPathwayGuide is a web based pathway analysis tool that goes beyond the typical statistical... - June 25, 2014 - Advaita Corporation

Arbovax Closing in on Vaccine for Chikungunya

Arbovax, Inc., a clinical stage biotechnology company, has successfully demonstrated in an animal model the efficacy of its vaccine technology for the treatment of Chikungunya, a mosquito borne virus that has recently emerged in the US. “There was a major outbreak in the Caribbean that... - June 21, 2014 - Arbovax Inc

AveXis to Present at Piper Jaffray GenomeRX Symposium

AveXis, a clinical stage synthetic biology platform company, today announced that Mr. John Carbona, Chief Executive Officer and other members of the AveXis team will participate in the panel discussion “The Power Alley: Gene Therapy For Neuromuscular Disorders” at the Piper Jaffray... - June 20, 2014 - AveXis Inc.

Second Annual Eclipse IP Futures Conference Delivers Real World Insights on Monetizing Intellectual Property

Patent Value, America Invents Act, and “Patent Trolls” Big Part of Conversation at Event Hosted by RTI International, Neopatents, NC COIN - June 20, 2014 - COIN

MoBiTec GmbH, Germany, and Invent Biotechnologies Inc., USA, Sign Distribution Agreement for the European Market

MoBiTec GmbH, Germany, focused on selling products for life science research, has entered into a distribution agreement with Invent Biotechnologies, Inc., USA. Together with Invent Biotechnologies, MoBiTec expands its portfolio of premier brands. - June 19, 2014 - MoBiTec GmbH

VIRUN® & Pacific Deep Ocean Biotech Combine Natural Mineral Complexes with OmegaH2O® EPA and DHA for Foods, Beverages & Supplements

Virun, and Pacific Deep Ocean Biotech (PDOB), work together to provide mineral complexes that are derived from the ocean with Omega-3 EPA and DHA that deliver clean label claim and eco-friendly sustainable solutions. The combination allows a source for mineral complexes in VIRUN’s patent and patents-pending technologies that naturally yield low metal content to avoid reactivity with omega-3 EPA and DHA, all-the-while delivering a consistent level of Calcium, Sodium, Potassium and Magnesium. - June 18, 2014 - VIRUN

NC COIN, Shanahan Law Group, NC Biotechnology Center Announce Start Up and Early Stage Legal Series

Informative Five-Week seminar Series to Cover Topics from Business Formation, to Fund Raising and Exits, to IP Issues to International Business Transactions - June 14, 2014 - COIN

MoBiTec Launches SpeedBlot (His) – A Strikingly Fast and Easy-To-Use Western Blot Stain for His-Tagged Proteins

Instant detection of poly-histidine tagged proteins on nitrocellulose membrane with SpeedBlot (His) is easy and does not require relevant hands-on time. Even 0.1 pmol detection limits can be achieved with this highly sensitive detection reagent. While common Western Blot protocols require 6 to 21 hours, staining with SpeedBlot (His) is completed after just about 90 minutes. - June 12, 2014 - MoBiTec GmbH

Discover the Next IDE Inhibitor with the Newly Launched SensoLyte® IDE Activity Assay

AnaSpec Launches Industry’s First FRET-based Assay for Measurement of Insulin Degrading Enzyme (IDE) Activity for inhibitor high throughput screening- the SensoLyte® 520 IDE Activity Assay Kit. - June 12, 2014 - AnaSpec, EGT Group

Women’s Health: Dr. Kathy Maupin Announces a Free Webinar to Answer Questions About Hormone Replacement

Hormone expert will answer questions about treatment for symptoms of menopause and testosterone deficiency through bioidentical hormone replacement therapy. - June 08, 2014 - BioBalance Health

AveXis to Present at Families of Spinal Muscular Atrophy Annual Conference

AveXis, a clinical stage synthetic biology platform company, today announced that Dr. Allan Kaspar, Chief Scientific Officer, will be presenting at The Family and Researcher Poster Session at The Annual Spinal Muscular Atrophy Conference, which will be held on Thursday, June 12, 2014 in National... - June 08, 2014 - AveXis Inc.

Recursion Pharmaceuticals Announces Dr. H. Perry Fell as the First Member of Business Advisory Panel

Recursion Pharmaceuticals, a biotech start-up in Salt Lake City today announced the formation of its Business Advisory Panel. The first appointment to the Advisory Panel is H. Perry Fell, MBA, Ph.D. Perry is a distinguished scientist and leader who most prominently co-founded Seattle Genetics (NASDAQ: SGEN) and served as its CEO from start-up through IPO. - June 05, 2014 - Recursion Pharmaceuticals

ACT Enters Phase I Human Clinical Trials with First-in-Class Anti-Cancer Drug Candidate

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced today that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in... - June 04, 2014 - Advanced Cancer Therapeutics

Recent Headlines Within Biopharmaceuticals & Biotherapeutics

Recent Headlines
Within Biopharmaceuticals & Biotherapeutics